At a glance
ClinicalIndex Comparison RecordPhase 2Recruiting· 100 target
Drug / intervention
WSD0922-FUdrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase I/II Multicenter, Open Label, Single-arm Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of WSD0922-FU in the Treatment of Advanced Non-small Cell Lung Cancer
In Brief
A Phase 2 clinical trial evaluating WSD0922-FU for EGFR Mutation Positive Advanced Non-Small Cell Lung Cancer. Currently recruiting, targeting 100 participants across 12 sites.
Detailed Summary
This study is a multicenter, open label, single-arm phase I/II clinical trial of WSD0922-FU for patients with locally advanced or metastatic non-small cell lung cancer whose disease has progressed with thrid-generation EGFR-TKI .
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesChina
Collaborators--
Timeline
Phase 2Recruiting
2025202620272028
Enrollment StartSep 2024
First PostedOct 2024
TodayJul 2026
Primary CompletionJun 2027
Study CompletionDec 2027
First PostedOct 8, 2024
Enrollment StartSep 4, 2024
Primary CompletionJun 30, 2027
Study CompletionDec 31, 2027
TodayJul 1, 2026
Enrollment to primary: 2.8 yearsPosted 1.7 years agoPrimary completion in 12 months
Interventions
WSD0922-FUdrug
Procedure: Biospecimen Collection - blood samples Undergo collection of blood samples Procedure: Computed Tomography and/or Magnetic Resonance Imaging Undergo CT and/or MRI Drug: WSD0922-FU Given PO